PreOperative Endocrine Therapy for Individualised Care With Abemaciclib

Summary

POETIC-A is a phase 3 trial which targets post-menopausal primary breast cancer patients with a high 5-year risk of relapse as determined by a high Ki67 after 2 weeks aromatase inhibitor therapy pre-surgery. Eligible patients will be randomised to standard adjuvant endocrine therapy alone or standard adjuvant endocrine therapy with a CDK4/6 inhibitor called abemaciclib.

Timeline

Start

2020-12-23

Primary completion

2030-10

Completion

2030-10

Publications

• Harder H, Jenkins V, Fallowfield L. Perceptions and lived experiences with abemaciclib and endocrine therapy for early breast cancer: a rapid communication. Future Oncol. 2026 Jun;22(13):1533-1539. doi: 10.1080/14796694.2026.2672132. Epub 2026 May 22.

Drugs

Indications